论文部分内容阅读
目的评价沙格列汀与二甲双胍联用治疗初诊2型糖尿病患者的疗效,探讨其临床适用性。方法选择从2012年5月~2014年4月于我院接受治疗的96例初诊2型糖尿病患者,随机分为研究组48例和对照组48例,对照组患者采用单纯的二甲双胍给予治疗,研究组患者采用沙格列汀联合二甲双胍进行治疗。观察两组患者治疗前后的FBG、2h PBG、Hb Alc等生化指标以及临床疗效。结果治疗后,两组患者的各项指标与治疗前比较均有所改善,而治疗后,研究组患者的FBG、2h PBG、Hb Alc等指标明显低于对照组,总有效率明显高于对照组,差异均具有统计学意义(P<0.05)。结论沙格列汀与二甲双胍联用可以显著控制初诊2型糖尿病患者的血糖,效果良好,适合临床长期推广应用。
Objective To evaluate the efficacy of saxagliptin and metformin in the treatment of newly diagnosed type 2 diabetic patients and to explore its clinical applicability. Methods A total of 96 newly diagnosed type 2 diabetic patients treated in our hospital from May 2012 to April 2014 were randomly divided into study group (48 cases) and control group (48 cases). Patients in the control group were treated with metformin alone. The study Patients in the group were treated with saxagliptin plus metformin. Two groups of patients before and after treatment FBG, 2h PBG, Hb Alc and other biochemical indicators and clinical efficacy. Results After treatment, the indexes in both groups improved compared with those before treatment. After treatment, the indexes of FBG, 2h PBG and Hb Alc in the study group were significantly lower than those in the control group, and the total effective rate was significantly higher than that in the control group Group, the differences were statistically significant (P <0.05). Conclusion Saxagliptin combined with metformin can significantly control the blood glucose in newly diagnosed type 2 diabetic patients with good effect and is suitable for long-term clinical application.